The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.
Publication
, Journal Article
Atiq, S; Hirshman, N; Shariff, A; Zhang, T
Published in: Urol Oncol
October 2023
Newly approved systemic treatment options for metastatic urothelial cancer (mUC) have diversified treatments and improved responses and survival for chemotherapy refractory disease. These systemic treatments have associated toxicities which need appropriate management for patients to stay on treatment and potentially have longer benefit from treatment. We review the expected toxicities of immune checkpoint inhibitors, FGFR inhibitors such as erdafitinib, and antibody drug conjugates such as enfortumab vedotin and sacituzumab govitecan.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Urol Oncol
DOI
EISSN
1873-2496
Publication Date
October 2023
Volume
41
Issue
10
Start / End Page
410 / 419
Location
United States
Related Subject Headings
- Urology & Nephrology
- Urinary Bladder Neoplasms
- Patients
- Immune Checkpoint Inhibitors
- Humans
- Carcinoma, Transitional Cell
- Cancer Vaccines
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Atiq, S., Hirshman, N., Shariff, A., & Zhang, T. (2023). The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer. Urol Oncol, 41(10), 410–419. https://doi.org/10.1016/j.urolonc.2021.10.002
Atiq, Saad, Nathan Hirshman, Afreen Shariff, and Tian Zhang. “The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.” Urol Oncol 41, no. 10 (October 2023): 410–19. https://doi.org/10.1016/j.urolonc.2021.10.002.
Atiq S, Hirshman N, Shariff A, Zhang T. The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer. Urol Oncol. 2023 Oct;41(10):410–9.
Atiq, Saad, et al. “The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.” Urol Oncol, vol. 41, no. 10, Oct. 2023, pp. 410–19. Pubmed, doi:10.1016/j.urolonc.2021.10.002.
Atiq S, Hirshman N, Shariff A, Zhang T. The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer. Urol Oncol. 2023 Oct;41(10):410–419.
Published In
Urol Oncol
DOI
EISSN
1873-2496
Publication Date
October 2023
Volume
41
Issue
10
Start / End Page
410 / 419
Location
United States
Related Subject Headings
- Urology & Nephrology
- Urinary Bladder Neoplasms
- Patients
- Immune Checkpoint Inhibitors
- Humans
- Carcinoma, Transitional Cell
- Cancer Vaccines
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis